Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • Monday
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/02/26
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing ObligationGlobeNewsWire • 08/31/26
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/26
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/03/26
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic SyndromesGlobeNewsWire • 06/11/26
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/26
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/08/26
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/16/26
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 03/09/26
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026GlobeNewsWire • 02/23/26